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Fine-scale mapping of the 4q24 locus identifies two independent 
loci associated with breast cancer risk
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Abstract
Background—A recent association study identified a common variant (rs9790517) at 4q24 to be 
associated with breast cancer risk. Independent association signals and potential functional 
variants in this locus have not been explored.
Methods—We conducted a fine-mapping analysis in 55,540 breast cancer cases and 51,168 
controls from the Breast Cancer Association Consortium.
Results—Conditional analyses identified two independent association signals among women of 
European ancestry, represented by rs9790517 (conditional p = 2.51 × 10−4; OR = 1.04; 95% CI 
1.02–1.07) and rs77928427 (p = 1.86 × 10−4; OR = 1.04; 95% CI 1.02–1.07). Functional 
annotation using data from the Encyclopedia of DNA Elements (ENCODE) project revealed two 
putative functional variants, rs62331150 and rs73838678 in linkage disequilibrium (LD) with 
rs9790517 (r2 ≥ 0.90) residing in the active promoter or enhancer, respectively, of the nearest 
gene, TET2. Both variants are located in DNase I hypersensitivity and transcription factor binding 
sites. Using data from both The Cancer Genome Atlas (TCGA) and Molecular Taxonomy of 
Breast Cancer International Consortium (METABRIC), we showed that rs62331150 was 
associated with level of expression of TET2 in breast normal and tumor tissue.
Conclusion—Our study identified two independent association signals at 4q24 in relation to 
breast cancer risk and suggested that observed association in this locus may be mediated through 
the regulation of TET2.
Impact—Fine-mapping study with large sample size warranted for identification of independent 
loci for breast cancer risk.
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Introduction
A common genetic variant at 4q24, rs9790517, was recently identified to be associated with 
breast cancer risk, through a combined analysis of genome-wide association studies 
(GWAS) together with data from a large association study using a custom array, iCOGS (1, 
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2). This risk variant, termed subsequently as the index SNP in this paper, is located in intron 
11 of TET2, a chromatin-remodeling gene that functions as a tumor suppressor. TET2 has 
been found to be frequently somatically mutated in multiple cancers, including breast cancer 
(3–9). However, the index SNP is located in a region with no evidence of functional 
significance. The initial GWAS reported only the most strongly statistically associated SNP 
in this region, although many other SNPs at the same locus also may be associated with 
breast cancer risk, one or more of which are causally related to breast cancer risk. 
Comprehensive fine-scale mapping may help to identify the variants most likely to be 
functionally related to risk, and may enable the identification of additional independent 
signals.
Dense fine-scale mapping of GWAS-identified loci has successfully identified novel 
putative causative variants for several common diseases, including breast cancer (10–17). 
For example, previous fine-mapping studies of 5p15, 20q16, 2q35, 5q11 and 11q13 have 
identified multiple independent risk signals as well as potential causative variants in each 
region, using data from the Breast Cancer Association Consortium (BCAC) (12, 13,16, 18–
20). The index SNP (rs9790517) at 4q24 is close to another SNP, rs7679673 (r2 = 0.42, 23 
kb apart), which has been associated with prostate cancer (21). In this fine-mapping project, 
a dense set of SNPs in this 4q24 region was genotyped in genomic DNA samples obtained 
from 106,708 participants included in the BCAC. We then analyzed data from 3,912 
genotyped and imputed SNPs in this region in an attempt identify potential functional 
variants that may explain the observed association of genetic variants in this locus with 
breast cancer risk.
Materials and Methods
Study populations
The study included 55,540 breast cancer cases and 51,168 controls from 50 studies 
participating in the BCAC. Details of the studies, sample selection, and genotypes are 
described elsewhere (1). The dataset included 39 studies from European-ancestry 
populations (48, 155 cases and 43,612 controls), nine from Asian populations (6,269 cases 
and 6,624 controls) and two from populations of African ancestry (1,116 cases and 932 
controls).
Genotyping of 4q24
A dense set of SNPs at 4q24 were selected for genotyping on iCOGS based on evidence of a 
prostate cancer associated SNP, rs7679673 (17), since at the time of the assay design this 
region had not yet been linked to breast cancer risk. An interval of 596kb (positions in chr4, 
105932103 – 106528262 from hg19) was identified based on all SNPs with r2 > 0.1 with the 
SNP rs7679673 based on HapMap 2 CEU (22). All SNPs in the interval were then identified 
from the 1000 Genomes Project CEU (April 2010)(23), together with HapMap 3, and we 
selected SNPs for genotyping which had an MAF > 2% in Europeans and an Illumina 
Design score > 0.8. From this set, all SNPs with r2 > 0.1 with SNP rs7679673 were selected, 
together with an additional set of SNPs to tag the remaining SNPs at r2 > 0.9. In total, 490 
SNPs were successfully genotyped and passed quality control. We imputed genotypes for 
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the remaining SNPs using the program IMPUTE2 (24) and the March 2012 release of the 
1000 Genomes Project as a reference. Those imputed SNPs with common SNPs (MAF > 
0.02) and imputation r2 > 0.3 were included in the current analysis.
Statistical analyses
For each genotyped and imputed SNP, we evaluated its association with breast cancer risk 
using a logistic regression model with adjustment for age, study site and principal 
components to correct for potential population stratification (the first six principal 
components, plus one additional principal component for the LMBC in analyses of the 
European ancestry data, or the first two principal components in the analyses of the Asian 
and African ancestry data), as previously described (1). Odds ratios (ORs) and 95% 
confidence intervals (CIs) were estimated under a log-additive model. We conducted 
separate analyses within European, Asian and African American populations.
To identify independent association signals, we performed stepwise forward logistic 
regression analyses for the associated SNPs with an MAF > 0.02 showing association at p < 
1 × 10−4 in the single marker SNP analysis. We used the Step function implemented in the R 
package (25) with the penalty K = 10 for inclusion of additional SNPs in the model. Since 
no SNPs showed p < 1 × 10−4 in the Asian or African populations, this analysis was 
performed only in the European population. The model was adjusted for the same factors as 
in the single SNP analysis. To define potentially causative variants, we computed a 
likelihood ratio for each SNP relative to the best associated SNP in each signal and excluded 
SNPs with a likelihood ratio < 1/100. Haplotype-specific ORs were estimated using 
haplo.stats in R, including age, study site, and the first six principal components, plus one 
additional principal component for the LMBC study.
Functional annotation
We annotated 29 candidate causative variants for potential functional significance using 
chromHMM annotation across nine ENCODE(26) cell lines: HMEC, GM12878, H1-hESC, 
K562, HepG2, HSMM, HUVEC, NHEK, and NHLF (27). For each variant, we investigated 
whether it is mapped to functional regions (i.e. promoter and enhancer) through chromatin 
states annotation from the UCSC Genome Browser (28). The epigenetic landscape of 
histone markers H3K4Me1, H3K4Me3, and H3K27Ac was also examined through layered 
histone tracks on seven ENCODE cell lines including GM12878, H1-hESC, K562, HSMM, 
HUVEC, NHEK, and NHLF from the UCSC Genome Browser. DNase I hypersensitive and 
TF ChIP-Seq datasets were investigated in all available ENCODE cell lines, including breast 
normal cell line, HMEC, and breast cancer cell lines, T-47D and MCF-7. Two publicly 
available tools, RegulomeDB (29) and HaploReg v2(30), were also used to evaluate those 
likely functional variants (9, 31). In addition, we also investigated whether each variant is 
overlapped with regulatory elements of enhancers and TSS from two previous studies 
including Hnisz et al (32) and Andersson et al (FANTOM5 project) (33). Chromatin 
Interaction Analysis by Paired End Tag (ChIA-PET) (mediated by RNA polymerase 2) data 
from MCF7 cell were downloaded from GEO (GSE39495) and the ggbio R package was 
used to represent the interactions between cell enhancers (containing a strongly associated 
variant) and a predicted gene promoter.
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TCGA data resource and eQTL analysis
We downloaded RNA-Seq V2 data (level 3) of 1,006 breast cancer tumor tissues from the 
TCGA data portal (34). DNA methylation data measured by the Illumina 
HumanMethylation450 BeadChip were also retrieved from TCGA level 3 data. We also 
downloaded level 3 SNP data genotyped using the Affymetrix SNP 6.0 array. Copy Number 
Alteration (CNA) data for genes PPA2, ARHGEF38, INTS12, GSTCD and TET2 at 4q24 for 
TCGA samples were collected from the CbioPortal (35). We analyzed a total of 645 breast 
tumor tissues in Caucasian population including matched CNV, genotype and expression 
data.
We performed eQTL analysis in TCGA tumor tissues described above. We applied several 
steps to reduce the batch or other technical effects on gene expressions following the 
approach described by Pickrell et al (36). First, the RNA-Seq by Expectation-Maximization 
value of each gene was log2 transformed and those genes with a median expression level of 
0 across tissues were removed. We then performed the principal component correction on 
gene expression to remove potential batch effects. A linear regression of expression values 
on the first five principal components was constructed and the residuals were used to replace 
the expression values of each gene among tissues. To make the data better conform to the 
linear model for the eQTL analysis, we further transformed the gene expression levels to fit 
quantiles of N(0, 1) distribution based on the ranks of the expression values to their 
respective quantiles. Residual linear regression models were constructed to detect eQTLs, 
while adjusting for methylation and CNA, according to the approach used by Li et al (37).
We also extracted matched genotypes and gene expression levels as described above in a 
total of 135 tumor-adjacent normal breast tissues in European ancestry individuals from the 
METABRIC project (38). Gene expression profiling was generated on the Illumina HT12 v3 
microarray platform and probe-level measurements were used. Genotyping was performed 
on the Affymetrix SNP 6.0 with genotypes being imputed using the 1000 Genomes March 
2012 CEU reference panel. Matrix eQTL was performed for evaluating the association 
between genotypes and gene expression levels (39).
Results
Association Analyses
We evaluated associations for 490 genotyped and 3,422 well-imputed SNPs at 4q24 
spanning 596 kb (positions in chr4: 105932103 – 106528262 from hg19) in 48,155 cases 
and 43,612 controls of European descent. A total of 29 variants were significantly associated 
with breast-cancer risk at p < 1 × 10−4 (Figure 1, Supplementary Table 1). Of these, 15 
variants were directly genotyped and 14 were imputed with r2 > 0.9. All risk-associated 
variants had minor allele frequencies (MAF) > 0.05. The index SNP, rs9790517, showed 
strong evidence of a significant association with breast cancer risk (OR = 1.05; 95% CI 
1.03–1.08; p = 5.44 × 10−6), which was consistent with the report from the original study 
(1). The strongest association was, however, found for an imputed SNP rs73838678 (OR 
=1.12, 95% CI 1.07–1.17; p = 1.29 × 10−6).
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To identify potential independent association signals, we carried out forward stepwise 
logistic regression analysis on SNPs associated with breast cancer at p < 1 × 10−4. Two 
independent association signals were revealed: index SNP rs9790517 (conditional p = 2.51 
× 10−4, after adjustment for the SNP in the second signal) and SNP rs77928427 (conditional 
p = 1.86 × 10−4 after adjusting for the index SNP) (Table 1). The index SNP rs9790517 in 
signal 1 was in weak LD with the SNP rs77928427 in the second risk signal (r2 = 0.04). 
These two SNPs are more than 300kb from each other.
We performed similar analyses, restricting to cases with estrogen receptor positive (ER+) 
cancer and identified 17 variants associated with ER+ breast cancer risk at p < 1 × 10−4 in 
women of European ancestry. No SNP was found to be associated with ER-negative (ER−) 
disease at p < 1 × 10−4. However, the per-allele ORs for the two SNPs independently 
associated with overall breast cancer risk were similar for ER− and ER+ disease (Table 1; 
all tests of heterogeneity by ER-status p > 0.10). Conditional analysis yielded similar 
associations for ER+ breast cancer to those for overall breast cancer for the two 
independently associated SNPs.
We performed haplotype analysis based on the top SNPs from the two signals: rs9790517 
and rs77928427 in European descendants. Three major haplotypes were observed. 
Compared with the most common haplotype carrying the common allele at both SNPs, 
haplotype TA carrying two risk alleles showed the strongest association with breast cancer 
risk (OR = 1.11; 95% CI 1.07–1.15; p = 2.31 × 10−8) (Table 2). The frequency of this 
haplotype was 9.4%. Haplotypes CA and TC, carrying the risk allele in either signal 1 or 2, 
also were associated with elevated risk of breast cancer, although the association was only 
marginally significant. Thus, the haplotype analyses were consistent with the hypothesis that 
there are two independently associated variants in the region.
We compared the average age among those cases carrying risk and non-risk alleles of 
rs9790517. Interestingly, we observed that the cases carrying risk alleles were slightly 
younger than those carrying non-risk alleles (average age: 57.54, 57.62 and 57.64 
respectively for patients carrying alleles TT, TC and CC of rs9790517; p < 2 × 10−16). No 
such pattern was observed for rs77928427.
We carried out association analysis for all SNPs with breast cancer in subjects of Asian and 
African descent. None of the SNPs identified in women of European ancestry as associated 
at p < 10−4 showed a significant association in either Asians or African women at p < 0.05 
(Table 3). However, the 95%CI for the OR estimates in Asians and Africans included the 
point estimate in Europeans for both of the two top independent SNPs. We found one SNP 
associated with breast cancer risk in Asians and three in Africans, at p < 0.01 (strongest 
signal rs1116764: OR 1.10; 95% CI 1.04–1.16; p = 4.21 × 10−4), none of these SNPs were 
in LD with the two independent association signals identified in European women (Table 3).
Functional Annotation
We used a likelihood ratio > 1:100 relative to the best associated SNP in each signal to 
select candidate variants for functional annotation in order to identify potentially causative 
variants in this region (Supplementary Table 1). In total, 29 SNPs were identified including 
Guo et al. Page 5
Cancer Epidemiol Biomarkers Prev. Author manuscript; available in PMC 2016 November 01.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
24 for signal 1 and 5 for signal 2. Of these, 17 SNPs in signal 1 were strongly correlated 
with the original index SNP rs9790517, and the remainder were more weakly correlated. All 
SNPs were evaluated using DNase-Seq and ChIP-Seq data from the ENCODE project. The 
most promising evidence for functionality was found for SNPs rs62331150 and rs73838678, 
both in LD with rs9790517 (r2 = 0.98 and r2 = 0.09, respectively) in signal 1.The annotation 
from chromatin states (27) revealed that rs62331150 resides an active promoter region, and 
rs73838678 in a strong enhancer region, on several ENCODE cell lines including HMEC 
(Human Mammary Epithelial Cell) but not for other SNPs in either signal 1 or 2 (Figure 
2A). The active promoter associated histone marks (H3K4Me3 and H3K27Ac) and enhancer 
associated histone marker H3K27Ac were enriched in the intervals containing rs62331150 
and rs73838678, respectively, in several ENCODE cells, and both SNPs were also found to 
be located in or near a DNase I hypersensitive site (DHS) (Figure 2A, B). In addition, both 
variants were found to overlap with predicted enhancer regions of TET2 in multiple cells 
including HMEC as reported in a recent study (32). None of the other SNPs in signal 1, and 
none of the 5 SNPs in signal 2 fell into a strong annotated promoter or enhancer region in 
those cells.
To identify putative gene targets, we examined the annotation of TSS and TSS-associated 
enhancers using Cap Analysis of Gene Expression (CAGE) from the FANTOM5 project 
(23). We found that rs62331150 and rs73838678 reside in regulatory elements of enhancers 
associated with transcription start sites (TSS) and TSS of TET2 in multiple cells (Figure 
2A). We also examined potential functional chromatin interactions between distal and 
proximal regulatory transcription-factor binding sites and the promoters at the risk regions 
using ChIA-PET data. ChIA-PET data for Pol2 in MCF-7 breast tumor derived cells showed 
multiple chromosomal interactions across the entire region, but these interactions were 
particularly dense in the vicinity of the TET2 promoter region, encompassing the strongest 
candidate causal variant rs62331150 and rs73838678 (Figure 2A).
A search of RegulomeDB indicated that rs62331150 and rs73838678 were annotated to lie 
in the breast cancer related transcription factor (TF) SP1 (Specificity Protein 1) and PR 
(progesterone receptor) (40, 41) predicted binding motifs, respectively (Figure 2B). We 
observed that the G nucleotide was more frequently found in the SP1 motif than the T 
nucleotide, indicating that the SP1 may preferentially bind to the reference G allele (Figure 
2B). For variant rs73838678, no significant allelic frequency difference in the PR motif was 
observed. Using ChIP-Seq data from a total of 161 TFs from the ENCODE project (ChIP-
Seq V3), we found that both variants are located in multiple TF binding sites (Figure 2B). 
As an example, ChIP-Seq binding peaks of breast cancer-related TFs, EGR1 and NIFC, 
harbor the variant rs62331150 and rs73838678, respectively (42, 43). In particular, we 
observed that P300, marking the active enhancer, was found to bind close to both variants in 
multiple ENCODE cell lines, suggesting that the variant in the region may lead to TET2 
transcriptional activation.
Gene expression analyses
We used both The Cancer Genome Atlas (TCGA) and Molecular Taxonomy of Breast 
Cancer International Consortium (METABRIC) data to examine the association of the 
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putative functional SNP rs62331150 and rs73838678 with expression of TET2 and several 
other neighboring genes, including PPA2, ARHGEF38, INTS12, and GSTCD, in breast 
cancer tissues. No significant correlations with any genes were observed for variant 
rs73838678. Variant rs62331150 was weakly correlated with TET2 expression in both 
datasets (p = 0.039 and p=0.025 respectively for TCGA and METABRIC), the reference 
allele G being associated with increased expression relative to the risk allele T (Figure 3). 
The result was consistent with the observation from our functional annotation that SP1 may 
preferentially bind to the reference G allele, leading to a significant increase in TET2 
transcription activation. No correlation between rs62331150 and the expression of any other 
gene in the region was found in either dataset. Overall, our findings supported a hypothesis 
that TET2 is the target gene for the signal 1 association, and that the association with breast 
cancer risk may be mediated through regulation of TET2 gene expression. The result is also 
in line with previous findings that TET2 functions as a tumor suppressor and its high 
expression level may reduce breast cancer risk (44, 45).
Discussion
In this study, we identified two independent association signals at 4q24 in women of 
European ancestry. Statistical analyses reduced the set of likely causative variants to 29. 
Using functional genomic data, we provided strong evidence for two variants as functional 
variants. Our study suggests that the breast cancer risk may be mediated through their 
regulation of TET2 gene expression.
In our initial single marker analysis, we observed that the majority of variants, including the 
index SNP, were located in or near the TET2 gene region. Through eQTL analysis based on 
TCGA data, we found that multiple SNPs in signal 1 were correlated with TET2 expression, 
which was expected given their strong LD with each others. Of those SNPs, rs62331150 
resides in the promoter of TET2. Although eQTL analysis is helpful to identify potential 
target genes, it is difficult to use eQTL results to pinpoint the causal variant particularly 
when multiple SNPs are in strong LD. In addition to residing in the promoter region of the 
TERT2, the variant rs62331150 was also found to be located in the binding sites of multiple 
TFs including the breast cancer related TF EGR1, potentially affecting the binding affinities 
of specific TFs. Interestingly, the putative functional SNP rs62331150 is close to SNP 
rs7679673 that has been associated with prostate cancer risk (21), indicating that TET2 gene 
may also be involved in prostate cancer risk. In comparison to rs62331150, rs73838678 in 
signal 1 was not found to have a significant association with TET2 and any other nearby 
genes. One possible reason is that the statistical power is low for rs73838678 due to its 
relative low allele frequency (MAF = 0.049). We also could not exclude the other possible 
target genes for rs73838678. Future studies using in vitro and in vivo assays are warranted to 
verify this conclusion.
Cumulative evidence shows that TET2 has an important function in tumor suppression. This 
gene can alter the epigenetic status of DNA base methylcytosine to 5-
hydroxymethylcytosine and therefore, have a genome-wide scale of influence on gene 
expression (46–48). Accordingly, TET2 gene dysregulation could cause aberrant DNA 
methylations and consequently contribute to cancer development (3–6, 45, 49). Here, we 
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reported TET2 as a candidate susceptibility gene for both ER+ and ER− breast cancer types. 
Although the associations for the top SNPs, rs9790517 and rs77928427, with breast cancer 
risk in Asian and African-ancestry populations were not statistically significant, likely due to 
a small sample size, the direction of the associations was mostly consistent in all population, 
suggesting that the TET2 gene play a similar role in the etiology of breast cancer in all three 
populations.
Although our fine-mapping analysis represents the most comprehensive analysis of variants 
at 4q24 thus far, many SNPs, particularly rare variants, cannot be imputed. Deep sequencing 
of this region may reveal additional risk variants for breast cancer. For example, 
rs76682196, located 884 bp upstream of rs62331150, was found to be potentially functional 
using the ENCODE data. The variant is present in DHS and TFs sites. In particular, it lies in 
the ERα (Estrogen Receptor-α) predicted binding motif and ChIP-Seq peak in breast cancer 
cell line T-47D. However, this variant was not included in the study due to its low frequency 
(MAF < 0.01) in populations from all three ethnic groups.
In conclusion, this dense fine-mapping study identified two independent association signals 
with breast cancer risk at 4q24, increasing the estimated familial relative risk of breast 
cancer explained by this locus from the original 0.07% to 0.15% among women of European 
descent. Functional analyses revealed one potentially functional variant, rs62331150. The 
risk allele is associated with lower expression of TET2, consistent with previous findings 
that this gene acts as a tumor suppressor.
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Figure 1. Regional plot of genetic variants associated with breast cancer risk at 4q24
A) The index SNP rs9790517 is plotted in diamond purple. The LD (r2) for the index SNP 
with each SNP was computed based on European ancestry subjects included in the 1000 
Genome Mar 2012 EUR. P values were from the single-marker analysis based on logistic 
regression models after adjusted for age, study sites and the first six principal components 
plus one additional principal component for the LMBC in analyses of data from European 
descendants. The plot was generated using LocusZoom (50).
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Figure 2. Functional annotation of SNPs association with breast cancer risk at 4q24
A) Epigenetic landscape at 4q24 risk locus for breast cancer. From top to bottom, RefSeq 
genes (TET2 and PPA2), layered H3K4Me1, H3K4Me3 and H3K27Ac histone 
modifications, DNase clusters, annotation using chromatin states on the ENCODE cell lines, 
and H3K27Ac histone modification in MCF-7, predicted enhancers reported in the Hnisz et 
al. study, regulatory elements of enhancers associated with TSS and TSSs from the 
FANTOM5 project and ChIA-PET interactions in MCF-7 cell (mediated by RNA 
polymerase 2) between enhancers and TET2 promoter are shown. The signals of different 
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layered histone modifications from the same ENCODE cell line are shown in the same color 
(The detailed color scheme for each ENCODE cell line described in the UCSC genome 
browser). The red and orange colors in chromatin states refer to active promoter and strong 
enhancer regions, respectively (The detailed color scheme of the chromatin states described 
in the previous study (27)). For ChIA-PET track, black lines represented interactions with 
the promoter region (−1500/+500) of TET2, and gray lines represent chromatin interactions 
that do not involve the TET2 promoter region. Purple and green lines represent interactions 
within +/− 500pb of rs73838678 and rs62331150 variants, respectively. B) Epigenetic 
signals of two potential functional variants rs73838678 and rs62331150. From top to 
bottom, lanes showing that the variant mapped to TF predicted binding motifs, TF ChIP-Seq 
binding peaks and DNase I hypersensitivity sites. The corresponding location of the variant 
is indicated by dashed line. C) LD plot for breast cancer risk associated SNPs at 4q24. In the 
top lane, two SNPs representing independent association signals are indicated by the black 
arrows. The index SNP is indicated by the red arrow. In the bottom lane, two LD SNP 
blocks were shown based on r2 values, which were computed based on the genotype data 
from the BCAC.
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Figure 3. The association between SNP rs62331150 and TET2 expression in breast cancer tissues 
from TCGA
The reference allele G of rs62331150 is significantly associated with the increased gene 
expression relative to the risk allele T.
Guo et al. Page 22
Cancer Epidemiol Biomarkers Prev. Author manuscript; available in PMC 2016 November 01.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
Guo et al. Page 23
Ta
bl
e 
1
Id
en
tif
ic
at
io
n 
of
 tw
o 
in
de
pe
nd
en
t a
ss
oc
ia
tio
n 
sig
na
ls 
fo
r o
ve
ra
ll 
br
ea
st 
ca
nc
er
 ri
sk
 a
m
on
g 
w
om
en
 o
f E
ur
op
ea
n 
an
ce
str
y.
Si
gn
al
SN
Ps
Po
sit
io
n
(h
g 1
9)
A
lle
le
sb
R
A
F
LD
c (r
2 )
Si
ng
le
 M
ar
ke
r A
na
ly
sis
C
on
di
tio
na
l A
na
ly
sis
O
R
 (9
5%
 C
I) 
d
P 
tr
en
dd
O
R
 (9
5%
 C
I)e
P 
tr
en
de
A
ll 
ca
se
s (
48
,15
5 c
as
es 
an
d 4
3,6
12
 co
nt
ro
ls)
1f
rs
97
90
51
7a
10
60
84
77
8
T/
C
0.
23
-
1.
05
(1.
03
–1
.08
)
5.
44
 ×
 1
0−
6
1.
04
(1.
02
–1
.07
)
2.
51
 ×
 1
0−
4
2g
rs
77
92
84
27
10
63
56
76
1
A
/C
0.
24
0.
04
1.
05
(1.
03
–1
.08
)
4.
07
 ×
 1
0−
6
1.
04
(1.
02
–1
.07
)
1.
86
 ×
 1
0−
4
ER
 (+
) (
28
,03
8 c
as
es 
an
d 4
3,6
12
 co
nt
ro
ls)
1
rs
97
90
51
7 
a
10
60
84
77
8
T/
C
0.
23
-
1.
06
(1.
03
–1
.09
)
1.
20
 ×
 1
0−
5
1.
05
(1.
02
–1
.08
)
2.
49
 ×
 1
0−
4
2
rs
77
92
84
27
10
63
56
76
1
A
/C
0.
24
0.
04
1.
05
(1.
02
–1
.08
)
1.
40
×1
0−
4
1.
04
(1.
01
–1
.07
)
3.
07
 ×
 1
0−
3
ER
 (−
) (
7,7
86
 ca
ses
 an
d 4
3,6
12
 co
nt
ro
ls)
1
rs
97
90
51
7 
a
10
60
84
77
8
T/
C
0.
22
-
1.
04
(0.
99
–1
.08
)
0.
16
1.
02
(0.
98
–1
.07
)
0.
33
96
2
rs
77
92
84
27
10
63
56
76
1
A
/C
0.
24
0.
04
1.
05
(1.
01
–1
.09
)
0.
03
1.
04
(1.
00
–1
.09
)
0.
05
08
A
bb
re
vi
at
io
ns
: O
R,
 o
dd
s r
at
io
; C
I, 
co
nf
id
en
ce
 in
te
rv
al
; R
A
F,
 ri
sk
 a
lle
le
 fr
eq
ue
nc
y
a
In
de
x 
SN
P.
b R
isk
/re
fe
re
nc
e 
al
le
le
; r
isk
 a
lle
le
s a
re
 sh
ow
n 
in
 b
ol
d.
c r
2  
fo
r l
in
ka
ge
 d
ise
qu
ili
br
iu
m
 w
ith
 th
e 
in
de
x 
SN
P 
rs
97
90
51
7.
d A
dju
ste
d f
or 
ag
e, 
stu
dy
 an
d t
he
 fir
st 
six
 an
d a
n a
dd
itio
na
l P
C 
for
 LM
BC
 st
ud
y.
e I
nc
lu
de
d 
bo
th
 to
p 
SN
Ps
 a
nd
 a
dju
ste
d f
or 
oth
er 
top
 SN
Ps
, a
ge
, st
ud
y s
ite
s a
nd
 th
e f
irs
t s
ix 
an
d a
n a
dd
itio
na
l P
C 
for
 LM
BC
 st
ud
y.
f A
 to
ta
l o
f 2
3 
SN
Ps
 c
an
no
t b
e 
ex
cl
ud
ed
 u
sin
g 
LR
 <
 1
/1
00
 a
s c
an
di
da
te
 c
au
sa
l v
ar
ia
nt
s (
see
 Su
pp
lem
en
tar
y t
ab
le 
1).
g A
 to
ta
l o
f 4
 S
N
Ps
 c
an
no
t b
e 
ex
cl
ud
ed
 u
sin
g 
LR
 <
 1
/1
00
 a
s c
an
di
da
te
 c
au
sa
l v
ar
ia
nt
s (
see
 Su
pp
lem
en
tar
y t
ab
le 
1)
Cancer Epidemiol Biomarkers Prev. Author manuscript; available in PMC 2016 November 01.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
Guo et al. Page 24
Ta
bl
e 
2
H
ap
lo
ty
pe
 a
na
ly
se
s o
f t
he
 le
ad
 S
N
Ps
 in
 tw
o 
in
de
pe
nd
en
t s
ig
na
ls 
in
 re
la
tio
n 
to
 b
re
as
t c
an
ce
r r
isk
 a
m
on
g 
w
om
en
 o
f E
ur
op
ea
n 
an
ce
str
y.
Si
gn
al
rs
97
90
51
7a
rs
77
92
84
27
%
b
O
R
(95
%
 C
I)c
P 
tr
en
dc
R
ef
er
en
ce
C
C
62
.1
R
ef
er
en
ce
 (1
.00
)
1
C
A
15
.1
1.
03
(1.
00
–1
.06
)
0.
06
2
T
C
13
.4
1.
03
(1.
00
–1
.06
)
0.
09
3
T
A
9.
4
1.
11
(1.
07
–1
.15
)
2.
31
 ×
 1
0−
8
A
bb
re
vi
at
io
ns
: O
R,
 o
dd
s r
at
io
; C
I, 
co
nf
id
en
ce
 in
te
rv
al
.
a
In
de
x 
SN
P.
b H
ap
lo
ty
pe
 fr
eq
ue
nc
y.
c A
dju
ste
d f
or 
ag
e, 
stu
dy
 an
d t
he
 fir
st 
six
 PC
s a
nd
 an
 ad
dit
ion
al 
PC
 fo
r L
MB
C 
stu
dy
.
Cancer Epidemiol Biomarkers Prev. Author manuscript; available in PMC 2016 November 01.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
Guo et al. Page 25
Ta
bl
e 
3
A
ss
oc
ia
tio
n 
of
 le
ad
 S
N
Ps
 id
en
tif
ie
d 
in
 w
om
en
 o
f E
ur
op
ea
n 
an
d 
no
n-
Eu
ro
pe
an
 d
es
ce
nt
 w
ith
 b
re
as
t c
an
ce
r r
isk
 a
m
on
g 
w
om
en
 o
f A
sia
n 
(6,
26
9 c
ase
s a
nd
 
6,
62
4 
co
nt
ro
ls)
 an
d A
fri
ca
n a
nc
est
ry 
(1,
11
6 c
ase
s a
nd
 93
2 c
on
tro
ls)
.
To
p 
SN
Ps
A
lle
le
sb
Si
ng
le
 M
ar
ke
r A
na
ly
sis
 (A
sia
n)
Si
ng
le
 M
ar
ke
r A
na
ly
sis
 (A
fri
ca
n)
R
A
F
LD
 (r
2 )c
O
R
 (9
5%
 C
I) 
d
P 
tr
en
dd
R
A
F
LD
 (r
2 )c
O
R
 (9
5%
 C
I) 
d
P 
tr
en
dd
Id
en
tif
ie
d 
in
 w
om
en
 o
f E
ur
op
ea
n 
de
sc
en
t
Si
gn
al
 1
rs
97
90
51
7a
T/
C
0.
60
-
1.
00
(0.
95
–1
.06
)
0.
93
0.
06
-
1.
21
(0.
88
–1
.55
)
0.
28
Si
gn
al
 2
rs
77
92
84
27
A
/C
0.
06
0.
01
1.
02
(0.
91
–1
.12
)
0.
50
0.
16
0
1.
03
(0.
85
–1
.22
)
0.
86
Id
en
tif
ie
d 
in
 w
om
en
 o
f n
on
-E
ur
op
ea
n 
de
sc
en
t
rs
11
16
76
4
G
/A
0.
66
0.
13
1.
10
(1.
04
–1
.16
)
4.
21
×1
0−
4
0.
89
0
1.
02
(0.
81
–1
.23
)
0.
98
rs
79
21
91
51
C
/T
N
A
0.
95
0
1.
63
(1.
13
–2
.13
)
7.
44
×1
0−
3
rs
11
20
95
27
8
C
/T
N
A
0.
95
0
1.
65
(1.
16
–2
.14
)
4.
13
×1
0−
3
rs
14
49
56
46
1
A
/T
N
A
0.
93
0
1.
56
(1.
12
–2
.01
)
6.
73
×1
0−
3
A
bb
re
vi
at
io
ns
: O
R,
 o
dd
s r
at
io
; C
I, 
co
nf
id
en
ce
 in
te
rv
al
; R
A
F,
 ri
sk
 a
lle
le
 fr
eq
ue
nc
y.
a
In
de
x 
SN
P
b R
isk
/re
fe
re
nc
e 
al
le
le
; r
isk
 a
lle
le
s a
re
 sh
ow
n 
in
 b
ol
d.
c r
2  
fo
r l
in
ka
ge
 d
ise
qu
ili
br
iu
m
 w
ith
 th
e 
in
de
x 
SN
P 
rs
97
90
51
7 
in
 A
sia
ns
 an
d 
A
fri
ca
ns
, r
es
pe
ct
iv
el
y.
d A
dju
ste
d f
or 
ag
e, 
stu
dy
 an
d t
he
 fir
st 
six
 PC
 an
d a
n a
dd
itio
na
l P
C 
for
 LM
BC
 st
ud
y.
Cancer Epidemiol Biomarkers Prev. Author manuscript; available in PMC 2016 November 01.
